Ashish Juvekar
Overview
Explore the profile of Ashish Juvekar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huarte E, Peel M, Juvekar A, Dube P, Sarah S, Stephens L, et al.
Immunotherapy
. 2021 Jun;
13(12):977-987.
PMID: 34184542
Graft-versus-host disease (GvHD) is a major complication arising in patients undergoing allogenic hematopoietic stem cell transplantation. We tested ruxolitinib (a selective JAK1/2 inhibitor) efficacy in three different preclinical models of...
2.
Huarte E, OConnor R, Peel M, Nunez-Cruz S, Leferovich J, Juvekar A, et al.
Clin Cancer Res
. 2020 Oct;
26(23):6299-6309.
PMID: 32998963
Purpose: T cells engineered to express a chimeric antigen receptor (CAR) are a promising cancer immunotherapy. Such targeted therapies have shown long-term relapse-free survival in patients with B-cell leukemia and...
3.
Covington M, He X, Scuron M, Li J, Collins R, Juvekar A, et al.
Eur J Pharmacol
. 2020 Aug;
885:173505.
PMID: 32861662
Pharmacological modulation of the Janus kinase (JAK) family has achieved clinically meaningful therapeutic outcomes for the treatment of inflammatory and hematopoietic diseases. Several JAK1 selective compounds are being investigated clinically...
4.
Yeleswaram S, Smith P, Burn T, Covington M, Juvekar A, Li Y, et al.
Clin Immunol
. 2020 Jun;
218:108517.
PMID: 32585295
Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death. No vaccines or antiviral treatments have...
5.
Juvekar A, Hu H, Yadegarynia S, Lyssiotis C, Ullas S, Lien E, et al.
Proc Natl Acad Sci U S A
. 2016 Jul;
113(30):E4338-47.
PMID: 27402769
We previously reported that combining a phosphoinositide 3-kinase (PI3K) inhibitor with a poly-ADP Rib polymerase (PARP)-inhibitor enhanced DNA damage and cell death in breast cancers that have genetic aberrations in...
6.
Lien E, Lyssiotis C, Juvekar A, Hu H, Asara J, Cantley L, et al.
Nat Cell Biol
. 2016 Apr;
18(5):572-8.
PMID: 27088857
Cancer cells often select for mutations that enhance signalling through pathways that promote anabolic metabolism. Although the PI(3)K/Akt signalling pathway, which is frequently dysregulated in breast cancer, is a well-established...
7.
Hu H, Juvekar A, Lyssiotis C, Lien E, Albeck J, Oh D, et al.
Cell
. 2016 Jan;
164(3):433-46.
PMID: 26824656
The phosphoinositide 3-kinase (PI3K) pathway regulates multiple steps in glucose metabolism and also cytoskeletal functions, such as cell movement and attachment. Here, we show that PI3K directly coordinates glycolysis with...
8.
Juvekar A, Wulf G
Breast Cancer Res
. 2013 Apr;
15(2):308.
PMID: 23566381
The phosphoinositide 3-kinase (PI3K) pathway serves as a relay where signals that emanate from the cell membrane are received and converted into intracellular signals that promote proliferation and survival. Inhibitors...
9.
Juvekar A, Burga L, Hu H, Lunsford E, Ibrahim Y, Balmana J, et al.
Cancer Discov
. 2012 Aug;
2(11):1048-63.
PMID: 22915751
Unlabelled: There is a need to improve treatments for metastatic breast cancer. Here, we show the activation of the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways in a...
10.
Ramaswami S, Manna S, Juvekar A, Kennedy S, Vancura A, Vancurova I
Methods Mol Biol
. 2011 Nov;
809:121-34.
PMID: 22113272
Transcription factor NFκB comprises a family of proteins that serve as crucial regulators of genes involved in host immune and inflammatory responses, cell survival, proliferation, and differentiation. Since transcription of...